uniQure could see a major jump in attention if its Huntington’s treatment reaches the market, especially as one of the first therapies aimed at slowing the disease rather than just managing symptoms. The upside comes with big “all-eggs-in-one-basket” risk—approval, safety, and outsourced manufacturing all need to go right for the launch to succeed.Read more

Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment.Read more

LifeMD is trying to turn its telehealth platform into a broader, longer-term healthcare relationship by moving into new care areas, adding insurance coverage, and launching a membership program. The upside is steadier repeat customers and better efficiency through automation, but competition and refund-heavy categories could make growth bumpier than it looks.Read more

Blue Bird looks set to benefit as school districts replace aging buses and more public money pushes them toward cleaner, alternative‑fuel options. The big question is whether the company can keep improving how efficiently it builds buses and grows higher‑profit models if funding and policy support wobbles.Read more